Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

ICLR or CRL: Which Is the Better Value Stock Right Now?

ICLR or CRL: Which Is the Better Value Stock Right Now?

Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Charles River to Perform Plasmid Production for Ship of Theseus

Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market Following Fundamentals?

Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024

Charles River Laboratories Publishes 2023 Corporate Citizenship Report

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies

Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

Charles River (CRL) Extends Gene Therapy Offering With New Pact

Here's Why You Should Retain Charles River (CRL) Stock Now